IntraTherapies Institute

IntraTherapies Institute

Age Management Therapeutics




Founded in 2001, the IntraTherapies Institute is a catalyst in the evolution of health management and the integration of Longevity Science and Personalized Medicine within its group of proactive health enhancement programs.


Targeting the neurobiology of aging, IntraTherapies is committed to the highest standards in providing a platform for both preventive as well as interventional healthcare programs, IntraTherapies’ objectives are directed toward a clinical architecture addressing primary age-related disease categories and therapeutic processes on multiple levels of the healthcare continuum.


Within a medical framework comprising the specialties of neurology, endocrinology, oncology, hematology, and immunology, we strive for a comprehensive but cost effective approach enabling a new category of healthcare, Age Management Therapeutics. From both a preventive and interventional perspective, we enable an evidence-based platform of comprehensive care while providing an innovative clinical environment to foster important new medical discoveries. Founded in 2001, the IntraTherapies Institute actively pursues the ‘leading edge’ but guided by stringent oversight from a committed medical team interested in the progression from present day clinical choices to a near future of significant health improvement within current time frames for patients.


The ultimate objectives are to accelerate the availability of evidence-based clinically validated treatments to a broader population seeking the most promising, safe and effective medical programs for disease prevention, disease intervention and enhanced health.


We identify our primary Age Management Therapeutics programs within two categories of conjoined healthcare:


– Neurosystemic Medicine

– EpigeneticTherapeutics


IntraTherapies addresses three of the primary components of disease which present increasing challenges to US and global healthcare:


– Age-Related Neurodegenerative Disorders

– Late Stage Cancer Therapeutics

– Auto Immune and Inflammatory Diseases


IntraTherapies initial clinical objectives for patients provide a basis for overall equilibrium in health status enabled by evidence-based Neurosystemic Medicine. This approach is then conjoined with longevity science, pharmacogenomics and personalized medicine. The Age Management Therapeutics programs continue, further extending to preventive and interventional Epigenetic Cancer Therapeutics, with oncologist guided programs for each patient’s condition inclusive of Quality of Life factors. IntraTherapies Neurosystemic and Epigenetic therapeutic platforms utilize clinically-validated modalities directed toward optimal neurosystemic health, cancer preventive therapeutics, as well as late stage cancer interventional programs addressing a broad range of cancer categories.


IntraTherapies clinical alliances are also pursuing research in the emerging area of cancer preventive and interventional vaccines.


Creating an environment that resonates with responsible clinical innovation is our central mandate and evolving a new plateau in personalized medicine our primary mission.






This program is clinically directed toward to overall neuroendocrine support and is based on the primary principles of neuroendocrinology within a clinical program of personalized medicine. Neurosystemic Medicine addresses a spectrum of predictive age–related degenerative disorders and central nervous system functions with a group of Neurometabolic / Neuroendocrine regulating programs for optimal neuro-systemic effect coupled with neuro protective factors targeting cognitive function with potential neuroimmune benefits to support healthy aging.



This program is clinically directed toward Enhanced Intracellular Genetic Immunity (EIGI) via DNA Programmable Genetic Pharmacology.



IntraTherapies epigenetic programs are based on molecular cancer genetics and DNA Programmable Genetic Pharmacology, in conjunction with targeted combination therapies and pathway-specific programs targeted to achieve broader cancer interventional effect with enhanced safety at the cellular level, absent adverse impact on major cellular pathways. This approach, based on extensive human and other mammal studies noted below, appears to result in notable reduction of treatment toxicity levels across primary solid tumor cancer groups, specifically, Breast, Colon, Prostate, Non Small Cell Lung, Renal, and Ovarian cancer when further combined with Low Dose Metronomic Chemotherapy. All IntraTherapies treatment programs are based on oncologist / hematologist assessment of patient history, current treatment and health profile.


IECT – IntraTherapies Epigenetic Cancer Therapeutics is a Clinical Protocol based on Molecular cancer genetics and DNA Programmable Genetic Pharmacology directed toward inhibiting the Growth and Replication of Human Cancer Cells, Administered as a Monotherapy or Conjunctively with Metronomic Low Dose Chemotherapy.


Epigenetic Cancer Therapeutics is comprised of preventive and late stage cancer interventional therapeutic programs focused on enhanced intracellular genetic immunity. This is achieved by the integration of epigenetic programs combined with specific standard of care oncology medications with clinically-validated significantly reduced toxicity levels achieved via Metronomic Low Dose Chemotherapy.


Provided as a monotherapy or within a conjunctive treatment protocol, IntraTherapies Epigenetic Cancer Therapeutics has clinically demonstrated the ability to inhibit the growth, replication and proliferation of human cancer cells via DNA Methyltransferase Inhibitors. (See list of medical research institutions and recognized peer-reviewed publications below)


Additional neurosystemic clinical objectives include the measurable achievement of enhanced Quality of Life in managing Mood Disorders in Chronically ill patients.


* Note: These statements are based on published medical research data from the National Cancer Institute and other independent accredited medical institutions in peer-reviewed oncology / hematology publications worldwide which include:


– Indiana University School of Medicine; Indiana University Cancer Center – Departments of Surgery and Biochemistry/Molecular Biology

– Walther Oncology Center; Cancer Epigenetics Laboratory

– Spanish National Cancer Centre-Molecular Pathology Program

– Osaka University Graduate School of Medicine – Japan.


Published data referenced in this section appear in clinical oncology journals including:

– Cancer Research / American Association for Cancer Research;

– Current Opinion in Oncology, Journal of Pharmacological Sciences

– Elsevier Cancer Letters,

– Molecular Cancer Therapeutics

– Modern Pathology

– JNCI – Journal of the National Cancer Institute



This program is clinically directed toward Interventional Regulation of neuro-receptor and inflammation pathways for mediating chronic pain conditions but also including degenerative osteo-arthritis, TMJ, post-traumatic surgical pain as well as neck / back / spine disorders, chronic scoliosis, and extending to overall Intra-systemic mediation of multi-source chronic pain within the musculo-skeletal network.



This program is clinically directed toward Neuro receptor channel modulation for aura and non-aura-based chronic migraine and headache disorders.



This program is clinically directed toward targeted regulation of sleep disturbances related to circadian and other neuro mechanisms to alleviate acute and chronic insomnia as well as other inhibitors related to quality / continuity of sleep, and lack of restorative sleep.



This program is clinically directed to Rheumatoid Arthritis and all Immuno-Degenerative, Autoimmune and inflammatory Disorders resulting from the pathophysiologies of immuno-systemic compromise and chronic inflammation. This regimen is further directed toward inflammatory diseases such as Fibromyalgia, Lupus, Epstein-Barr, Chronic Fatigue Syndrome and the spectrum of approximately 105 immunity-related conditions.



This program is clinically directed toward Vision Optimization and Vascular Support for Long Term Eye Health.



This program is clinically directed toward Optimization of Circulatory, Vascular and Pulmonary Function with stabilization of Central and Sympathetic Nervous System.



This program is clinically directed toward anti-inflammatory vascular enhancement. It may provide dynamic oxygenation throughout all dermal/epidermal pathways.


Fact Sheet

October 2010


This Fact Sheet provides a broader research perspective and background guiding the genesis and development of IntraTherapies Neurosystemic Medicine and Epigenetic Cancer Therapeutics initiatives.


IntraTherapies Institute is initiating multi-site treatment programs for its oncology platform defined as IECT-IntraTherapies Epigenetic Cancer Therapeutics. The program utilizes known FDA approved compounds redirected to clinical targets previously unaddressed or unrecognized in the domains of age-related degenerative disorders within the construct of human senescence, and late stage cancer therapeutics.


IntraTherapies involvement with epigenetics originated in 2001 with a platform of neurometabolic / neuroendocrine regulating compounds intended to modulate the pathophysiologies of age related degenerative disorders and also confer neuroprotective benefits over time. Epigenetics refers to the reversible, heritable changes in gene regulation that occur without a change in DNA sequence. These changes, known as gene expression, can be addressed and regulated by pharmacologic processes. IECT developer Nathan Sassover identifies this as DNA-PGP: DNA Programmable Genetic Pharmacology. He has further unified IntraTherapies integrative approach within a personalized medicine framework he defines as Epigenetic Neurobiology.


The clinical pathways focusing on neurosystemic therapeutic and preventive protocols has evolved under the guidance of inventor and IECT developer Nathan Sassover and protocol designer, IntraTherapies Medical Advisor, Dr. Brent Treiger, MD, a research oncologist with a diverse fifteen year drug development background. Dr. Treiger is the developer of the ovarian cancer drug, Doxal. The impetus for launching the IECT cancer treatment program follows initial highly encouraging outcome in a clinical study of one Advanced Breast Cancer patient. Following eight weeks of outpatient treatment, PET /CT scan radiology reports confirmed significant tumor reduction, further corroborated by radiology oncologists clinical reports, as well as hematology analysis confirming improved cancer blood titers.


In the same time period, October 2008 – January 2009, parallel initial studies in a male patient with advanced Metastatic adenocarcinoma of the colon, also yielded encouraging meaningful reduction in key cancer titer blood levels as evidenced by hematology lab data confirmed by the attending physician administering the protocol during the eight week period.


Following these indicative outcomes, IntraTherapies has focused on deeper clinical inquiry related to possible relevance of IECT as a pathway-specific protocol for other solid tumor and hematologic cancers.



The IntraTherapies oncology platform is defined as :


IECT-IntraTherapies Epigenetic Cancer Therapeutics:

Clinical Protocols based on Molecular Cancer Genetics and DNA Programmable

Genetic Pharmacology to Inhibit the Growth, Replication and Proliferation of Human

Cancer Cells.


An eight month research initiative was focused on developing a basis for intervention in a total of six (6) solid tumor categories which serve as the basis for a broader Cancer Epigenetics Program with the objective of validating evidence-based safety / efficacy across the accepted ASCO (American Society of Clinical Oncologists) standards of PFS – Progression Free Survival / OS-Overall Survival, and QOL-Quality of Life measurable criteria.


The company has also established its IECT clinical management team which brings the requisite hematology / oncology experience to the task of initiating and administering this epigenetic treatment platform which utilizes known FDA approved compounds.


IECT- IntraTherapies Epigenetic Cancer Therapeutics Protocols target six solid tumor cancer lines and two hematological malignancies.


Advanced Stage III and IV Breast Cancer

Metastatic (Stage IV) Colon Cancer

Metastatic (Stage IV) Castration-Resistant Prostate Cancer (CRPC)

Advanced (Stage III and IV) Non Small Cell Lung Cancer (NSCLC)

Advanced (Stage III and IV) Ovarian Cancer

Metastatic (Stage IV) Renal Cell Carcinoma (Kidney Cancer


Hematologic Malignancies:

MDS – Myelodysplastic Syndrome – CML AML Leukemia


The multi-city cancer epigenetics program was initiated with World Cancer Institute, intended as a public forum and informational resource focusing on preventive and integrative cancer therapeutics, based on scientifically validated research within known medical research centers and corresponding publication of scientific studies in globally recognized peer-reviewed medical journals and professional medical associations and clinical presentations.


IntraTherapies primary objectives with the IECT programs presented here are to advance the clinical potential of DNA Demethylation and other Epigenetic cancer interventional and preventive modalities and techniques utilized singly or in conjunction with metronomic very low dose chemotherapy, further optimized by drug delivery methods which are easier to accommodate for patients with late stage cancers, where treatment outcomes are of diminishing effect in second, third and fourth line administration of conventional chemotherapy.


Provide a daily treatment regimen with functional transparency, clinically verified efficacy with evidence-based reduction in patient toxicity levels. In parallel, utilize clinically validated QOL instruments to assess long term quality of life factors attending extended treatment of late stage cancer patients without compromise of safety.


Within a majority of healthcare settings, it is an established statistically recognized fact that 80% of chemotherapeutic pharmaceutical and biopharmaceutical interventional treatments are not effective. In conjunction with World Cancer Institute, the broader objective is bringing a clinical focus and new pathways of currently accessible treatment to the most medically challenging condition known to mankind… human cancer.


Often times a clinical initiative can find itself well timed – in tune with an emerging consensus, a turning point which can have the unintended ‘side effect’ and benefit of serendipity. Such is the case with the Obama administration’s view of the importance of advancing the creation of research programs to treat and hopefully cure cancer, while, in the President’s words, “…bypassing the ‘choke point’ of clinical trials to bring important medical discoveries forward.”


In summary, the enlarging healthcare crisis in the US and increased focus redefining the ‘War on Cancer’ after marginal outcome over the past thirty years, warrants greatly accelerated attention in addressing the global progression of all forms of cancer and the life science developments which are seeking avenues of medically validated prevention and intervention.

Category: News
About The Author